Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp has received Australian Therapeutics Goods Administration approval for its ResAppDx-EU device
  • The device is now listed on the Australian Register of Therapeutic Goods
  • ResAppDx-EU is now pending De Novo classification for paediatric use in the United States

ResApp is up more than 11 per cent this afternoon after receiving Australian Therapeutics Goods Administration (TGA) approval for its ResAppDx-EU device.

Just recently, the device received CE Mark approval for version 2 of the app, which comes after the original version of ResAppDx-EU received CE Mark certification as a Class IIa medical device.

ResAppDx-EU is a mobile software application to be used by clinicians for the diagnosis of lower respiratory tract disease, croup, pneumonia, asthma, and bronchitis in infants and children.

The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose disease and provide timely and accurate information.

It is a software-only solution that runs on a smartphone and does not require any additional hardware or accessories.

This recent approval classes ResAppDx-EU as a Class IIa medical device, and it is now listed on the Australian Register of Therapeutic Goods (ARTG).

According to ResApp, most people will develop an acute respiratory tract infection every year and these infections are the most common acute illnesses seen in primary care.

In Australia, upper respiratory tract infections account for 3-4 million visits to GPs every year. Lower respiratory tract infections cause an additional three million visits.

It is hoped that ResApp’s device will minimise the time, money, and effort spent diagnosing infections.

“Achieving TGA approval is an important regulatory milestone that allows us to sell ResAppDx-EU in Australia, our home market,” CEO and Managing Director Tony Keating said.

“We believe that ResAppDx-EU will deliver strong health and economic benefits when used by clinicians in Australian emergency departments, urgent care clinics, GP offices and in the Australian telehealth industry, which has grown markedly in the last year,” he continued.

ResAppDx-EU is now pending De Novo classification for paediatric use in the United States with a follow-on TGA submission for adult use will be made shortly.

ResApp shares are up 11.1 per cent at 2:33 pm AEST trading for $27.5 cents apiece. Its market cap is valued at $171.9 million.

RAP by the numbers
More From The Market Herald
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.

" FijiKava (ASX:FIJ) raises $2.67m via SPP

Australian-Fijian health and wellness company FijiKava (FIJ) has raised $2,679,000 via its share purchase plan (SPP).
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering